Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia : an evidence-based review

Simple item page
dc.contributor.authorEmsley, Robin A.en_ZA
dc.contributor.authorKilian, Sanjaen_ZA
dc.date.accessioned2020-05-04T12:52:02Z
dc.date.available2020-05-04T12:52:02Z
dc.date.issued2018
dc.descriptionCITATION: Emsley, R. & Kilian, S. 2018. Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia : an evidence-based review. Neuropsychiatric Disease and Treatment, 14:205-223, doi:10.2147/NDT.S139633.
dc.descriptionThe original publication is available at https://www.dovepress.com
dc.description.abstractThe course of schizophrenia is characterized by multiple relapses, incomplete remission of symptoms, enduring cognitive deficits, and social and occupational functional impairments. Nonadherence to antipsychotic medication is a major determinant of this poor outcome. Long-acting injectable antipsychotics were developed specifically to address the nonadherence problem and are increasingly considered as an early treatment option, in an attempt to prevent accruing morbidity. This review focuses on paliperidone palmitate, the long-acting injectable (LAI) formulation of paliperidone. After considering the pharmacology of paliperidone palmitate, we review the randomized controlled trials, as well as pertinent observational, pragmatic studies for paliperidone once-monthly injections in schizophrenia. Finally, we review the recently introduced 3-monthly formulation of paliperidone palmitate. Taken together, the studies indicate that paliperidone palmitate (PP) has good efficacy compared with placebo and comparable with other antipsychotics including risperidone. The tolerability profile of PP is similar to that of risperidone, with the most important side effects being prolactin elevation, weight gain, and extrapyramidal symptoms. Advantages of PP include the extensive research database and clinical experience with paliperidone and its parent compound risperidone, the availability of different LAI formulations (once-monthly, 3-monthly, and perhaps even longer acting formulations in future), and the novel dose initiation procedure that provides rapid onset of action without the need for oral antipsychotic supplementation.en_ZA
dc.description.urihttps://www.dovepress.com/efficacy-and-safety-profile-of-paliperidone-palmitate-injections-in-th-peer-reviewed-article-NDT#
dc.description.versionPublisher's version
dc.format.extent19 pages
dc.identifier.citationEmsley, R. & Kilian, S. 2018. Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia : an evidence-based review. Neuropsychiatric Disease and Treatment, 14:205-223, doi:10.2147/NDT.S139633
dc.identifier.issn1178-2021 (online)
dc.identifier.issn1176-6328 (print)
dc.identifier.otherdoi:10.2147/NDT.S139633
dc.identifier.urihttp://hdl.handle.net/10019.1/108524
dc.language.isoen_ZAen_ZA
dc.publisherDove Medical Press
dc.rights.holderAuthors retain copyright
dc.subjectPaliperidone palmitate -- Effectivenessen_ZA
dc.subjectPaliperidone palmitate -- Side effectsen_ZA
dc.subjectAntipsychotic drugs -- Effectivenessen_ZA
dc.subjectSchizophrenia -- Treatmenten_ZA
dc.titleEfficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia : an evidence-based reviewen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
emsley_efficacy_2018.pdf
Size:
342.93 KB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Psychiatry)